Concepedia
Statistics
Publications
5
Citations
3K
H-Index
Active since
2007
Affiliations
Eli Lilly (United States)(Current)
University of California, Los Angeles
Pfizer (United States)
AstraZeneca (United States)
Sarepta Therapeutics (United States)
Tianle Hu is an author at Eli Lilly (United States) specializing in oncology, pharmacology, and epidemiologic methods.
Publications per year
2007–2020
A Genome-Wide Association Study of Type 2 Diabetes in Finns Detects Multiple Susceptibility Variants
Laura J. Scott, Karen L. Mohlke, Lori L. Bonnycastle et al. · Science · 2007 · 2.8K citations
Life Sciences, Endocrinology, Genetics +17
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
Lee S. Rosen, Jonathan W. Goldman, Alain P. Algazi et al. · Clinical Cancer Research · 2016 · 67 citations
Medicine, Oncology, Pharmacology +17
A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.
Geoffrey I. Shapiro, Lee S. Rosen, Anthony W. Tolcher et al. · Journal of Clinical Oncology · 2013 · 66 citations
Medicine, Oncology, Pharmacology +16
Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis
Ray Lin, Ji Lin, Satrajit Roychoudhury et al. · Figshare · 2020 · 45 citations · Full text
Public Health, Biostatistics, Oncology +13
Rejoinder to Letter to the Editor “The Hazards of Period Specific and Weighted Hazard Ratios”
Ray Lin, Ji Lin, Satrajit Roychoudhury et al. · Statistics in Biopharmaceutical Research · 2020 · 11 citations · Full text
Public Health, Biostatistics, Pharmacology +8
1–5 of 5